The purpose of this study is to evaluate the efficacy of Saturno II association on the control of ocular inflammation post-phacoemulsification

Inclusion Criteria:

• Participants of both sexes, aged 18 years or more;
• Participants presenting the diagnosis of cataract with indication for surgery by the phacoemulsification procedure;
• Participants who undergo surgery in only 1 eye at a time;
• Participants with intraocular pressure (IOP) ≤ 20 mmHg;
• Signed consent.

Exclusion Criteria:

• Used non-steroidal anti-inflammatory drugs or topical steroids or systemic inhalers within 21 days prior to randomization of the clinical trial;
• Performing the surgery for the second time, to correct the previous procedure or to change the lens;
• Decompensated glaucoma or ocular hypertension with IOP above 21 mmHg;
• Active ocular infectious diseases;
• History hypersensitivity to the active ingredients used in the study;
• Pregnancy or risk of pregnancy and lactating patients;
• History alcohol abuse or illicit drug use;
• Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
• Participation in clinical trial in the year prior to this study.